IMUX
IMMUNIC, INC.
Next earnings Aug 5, 2026 (before open) · consensus $-1.20 EPS
Last earnings +8.8% on 2026-05-13
$15.30
▲ +1.53%$15.30▲ +116.10%
over 1Y
L $5.10EODHDH $15.30
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.5%
1W+3.7%
1M+9.3%
3M+40.4%
YTD+162.4%
1Y+116.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 16 analysts
Strong Buy
Conservative balance sheet (liabilities/equity -4.60x).
Liabilities / equity -4.60x · latest
IMMUNIC, INC. shows limited reported revenue.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$91.7M | -$119M | -$99.2M | -$98.1M | -$103M |
| Net income | -$92.9M | -$120M | -$93.6M | -$101M | -$97.2M |
| Diluted EPS | -$3.93 | -$3.78 | -$2.11 | -$1.00 | -$0.62 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.98B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-4.9%
FCF yield-4.3%
Quality & risk
ROIC (est.)—
Free cash flow-$86.0M
Total debt—
Net cash$15.5M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+44.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- DEF 14A Proxy statement2026-05-29
- 8-K Reg FD disclosure2026-05-28
- 8-K Officer / director change2026-05-27
- 8-K Officer / director change2026-05-19
- 8-K Earnings results2026-05-13
- 10-Q Quarterly report2026-05-13
- S-3/A Shelf registration (potential raise)2026-04-30
- 8-K Officer / director change2026-04-28
- 8-K Material event2026-04-23
Recent filings
all on EDGAR ↗4Period ending 2026-05-222026-06-01open ↗3Period ending 2026-06-012026-06-01open ↗DEF 14APeriod ending 2026-06-292026-05-29open ↗8-KPeriod ending 2026-05-282026-05-28open ↗8-KPeriod ending 2026-05-222026-05-27open ↗3Period ending 2026-05-162026-05-19open ↗8-KPeriod ending 2026-05-162026-05-19open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗8-KPeriod ending 2026-05-132026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗SCHEDULE 13GFiling2026-05-06open ↗
Frequently asked
- Is IMMUNIC, INC. (IMUX) a buy?
- IMUX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -4.60x).
- What is IMMUNIC, INC.'s quality score?
- IMUX scores 40/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001280776, latest 10-Q filed 2026-05-13) · EODHD · as of 6/25/2026, 11:28:42 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.